Breast cancer online : BCO最新文献

{"title":"Bilateral breast reconstruction","authors":"J. Disa, C. M. McCarthy","doi":"10.1017/S1470903106003798","DOIUrl":"https://doi.org/10.1017/S1470903106003798","url":null,"abstract":"According to the American Cancer Society, more than 211 000 women in the USA were diagnosed with invasive breast cancer in 2005, (American Cancer Society. www.cancer.org . 2005). Nearly 65 000 of these women had postmastectomy reconstruction – a 100% increase from just over a decade ago, (American Society of Plastic Surgeons. www.plasticsurgery.org. 2005). A significant proportion of these women, will elect to undergo bilateral mastectomy for treatment and/or prophylaxis of breast cancer. Contemporary techniques provide numerous options for bilateral, postmastectomy reconstruction. Procedure selection will be based on a range of patient variables, including: availability of local, regional, and distant donor tissues for bilateral reconstruction, size and shape of the desired breasts, surgical risk, and most importantly, patient preference. Ultimately, the individualized selection of a reconstructive technique for each patient is a predominant factor in achieving a reconstructive success.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2006-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106003798","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive breast cancer trials","authors":"R. Rampaul, R. Pillarisetti","doi":"10.1017/S147090310600280X","DOIUrl":"https://doi.org/10.1017/S147090310600280X","url":null,"abstract":"Patients were randomized to mastectomy or breastconserving therapy (BCT) consisting of complete tumour excision, axillary dissection and radiation treatment. Seventy-eight per cent of patients accepted the procedure chosen for them by randomization, leaving (after all other protocol violations and other exclusions are accounted for) two groups: 619 patients for whom treatments had been randomly allocated and 136 who had chosen their treatment. In the BCT arm, treatment consisted of removal of the tumour-bearing part of the breast with enough normal tissue to ensure tumour-free margins at gross examination. All BCT patients were referred to radiotherapy to begin within 2–4 weeks after surgery. The target volume involved the whole breast. Regional lymph nodes were included only in high-risk patients. The dose was 50 Gy in 25 fractions over 5 weeks plus a boost to the tumour bed. Mastectomy consisted of removal of the entire breast through a transverse incision plus dissection of lowand mid-axilla.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"1 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2006-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S147090310600280X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science (July 2006)","authors":"R. Sutherland, J. Scorer","doi":"10.1017/S1470903106005700","DOIUrl":"https://doi.org/10.1017/S1470903106005700","url":null,"abstract":"1. Ai LB, Tao QA, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer [Abstract]. Carcinogenesis 2006; 27: 1341–1348. 2. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, Al-Katib W, Stitt LW, Uede T, Chambers AF, Tuck AB. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer [Abstract]. Am J Pathol 2006; 169: 233–246. 3. Allen-Brady K, Cannon-Albright LA, Neuhausen SL, Camp NJ. A role for XRCC4 in age at diagnosis and breast cancer risk [Abstract]. Cancer Epidem Biomark Prevent 2006; 15: 1306–1310. 4. Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a] anthracene-initiated mammary tumors and increase angiogenesis in Sprague–Dawley rats [Abstract]. Clin Cancer Res 2006; 12: 4062–4071. 5. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309 [Abstract]. J Natl Cancer Inst 2006; 98: 911–919. 6. Burrows C, Holly JMP, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes [Abstract]. Endocrinology 2006; 147: 3484–3500. 7. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta(9)-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation [Abstract]. Cancer Res 2006; 66: 6615–6621. 8. Cazzaniga M, Severi G, Casadio C, Chiapparini L, Veronesi U, Decensi A. Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer [Abstract]. Cancer Epidem Biomark Prevent 2006; 15: 1311–1315. 9. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden [Abstract]. Brit J Cancer 2006; 95: 118–122. 10. Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR, Holen I. Expression of receptor activator of nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables [Abstract]. J Clin Pathol 2006; 59: 716–720. 11. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha 2 as a potent","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106005700","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous angiosarcoma after breast conserving treatment of breast cancer","authors":"W. Eiermann, B. Ataseven","doi":"10.1017/S147090310600410X","DOIUrl":"https://doi.org/10.1017/S147090310600410X","url":null,"abstract":"In this case we describe a 77-year-old female who underwent breast conserving therapy, adjuvant radiotherapy and endocrine therapy (tamoxifen) for primary breast cancer (pT2, pN0, G3, R0, Mx, hormone receptor positive, Her2-negative). 28 month after completion of adjuvant radiotherapy new purple plaques and discolouration in the radiotherapy field were seen on the left breast, without other signs for example, lymphedema, inflammation, pain or itch. The histological result of a biopsy revealed a atypical vascular process (differential diagnosis: well differentiated angiosarcoma), no further differentiation was possible. At first a temporary improvement was seen. But 5 month later a clear progress happened. Now multifocal purple and red-brown coloured lesions up to 1.3 cm were spread all over the left breast (Fig. 1(a) and (b)). A second biopsy confirmed histological the Cutaneous angiosarcoma after breast conserving treatment of breast cancer","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S147090310600410X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic Science (August 2006)","authors":"R. Sutherland, J. Scorer","doi":"10.1017/S147090310600575X","DOIUrl":"https://doi.org/10.1017/S147090310600575X","url":null,"abstract":"1. Ai LB, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res 2006; 66: 7899–7909. 2. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66: 7734–7740. 3. Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, Zugmaier G, Pfizenmaier K, Knabbe C. A novel functional polymorphism in the transforming growth factor-beta(2) gene promoter and tumor progression in breast cancer. Cancer Res 2006; 66: 7554–7561. 4. Buterin T, Koch C, Naegeli H. Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis 2006; 27: 1567–1578. 5. Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai LM, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119: 944–954. 6. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, Conroy D, Luben R, Perkins B, Easton DF, Dunning AM, Esteller M, Ponder BAJ. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006; 27: 1661–1669. 7. Cook AC, Chambers AF, Turley EA, Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006; 281: 24381–24389. 8. Cotroneo MS, Merry GM, Haag JD, Lan H, Shepel LA, Gould MN. The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance. Oncogene 2006; 25: 5011–5017. 9. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene 2006; 25: 4998–5010. 10. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 2006; 66: 8219–8226. 11. Dejmek J, Safholm A, Nielsen CK, Andersson T, Leandersson K. Wnt-5a/Ca2 -induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42casein kinase 1 alpha signaling in human mammary epithelial cells. Mol Cell Biol 2006; 26: 6024–6036. 12. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 2006; 169: 633–642. 13. Dizin E, Gressier C, Magnard C, Ray H, Decimo D, Ohlmann T, Dalla Venezia N. BRCA1 interacts with poly(A)-binding protein – implication of BRCA1 in translation regulation. J Biol Chem 2006; 281: 24236–24246. 14. Fan C, Oh DS, Wessels L, Wei","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S147090310600575X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MammoSite brachytherapy: evolution and current status","authors":"R. Rabinovitch, A. Schwer","doi":"10.1017/S1470903106003658","DOIUrl":"https://doi.org/10.1017/S1470903106003658","url":null,"abstract":"Brachytherapy treatment consists of the insertion of radioactive sources into tissue to deliver radiotherapy directly to the tumor. Early treatment utilizing this method required intra-operative placement of 15–20 catheters by the radiation oncologist, a highly specialized procedure which limited its widespread use despite encouraging results from the first clinical trial and the benefits to the patient of receiving radiation treatment to only 2 cm of tissue beyond the borders of the lumpectomy cavity and the ability to complete the radiotherapy component of breast conserving treatment in 4–5 days, instead of the usual 4–6 weeks. The MammoSite ® Radiation Therapy System allows either a radiation oncologist or a surgeon to implant a much simplified brachytherapy device, thus increasing the number of patients who can receive this treatment. The device, which received FDA approval in May 2002, works by creating a cavity inside the lumpectomy site via a balloon. A high dose-rate brachytherapy source is inserted into this cavity, evenly irradiating the tissue at highest risk of containing residual cancer cells. Data collected since its approval show that MammoSite offers tumor control equal to traditional radiotherapy with fewer side effects of radiation exposure to nearby tissues. However, the invasive nature and high cost of this treatment mean that MammoSite should not be seen as the sole future direction of radiotherapy treatment delivery methods.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106003658","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of: Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions","authors":"G. Skliris, L. Murphy","doi":"10.1017/S1470903106005608","DOIUrl":"https://doi.org/10.1017/S1470903106005608","url":null,"abstract":"of (cid:1) promoter correlates with loss of ER- (cid:1) expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocrine-Related Cancer 2005; 12 : 903–916. Abstract of the original article The function of estrogen receptor beta (ER- (cid:1) ) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene. A decrease of ER- (cid:1) expression has been observed in ductal carcinoma in situ and invasive carcinomas as compared with benign mammary epithelial cells. The loss of ER- (cid:1) resulted in abnormal growth of mammary epithelial cells. We have previously shown that the mRNA expression of the ER- (cid:1) gene is almost totally suppressed in breast carcinomas from patients with a poor prognosis. Here we analyzed whether methylation changes in the different promoters of ER- (cid:1) are responsible for the loss of expression of the gene. A methylation assay with high specificity and sensitivity was developed, and a panel of breast tissue samples ( n (cid:2) 175) was characterized for methylation status. In contrast to benign breast, more than two-thirds of invasive breast cancers showed a high degree of methylation. Importantly, increased methylation was also detectable in numerous premalignant lesions. By analysis of breast tumors, previously characterized by gene-expression profiling, methylation was predominantly detected in a subgroup of patients with an unfavorable prognosis, suggesting a possible prognostic value of the ER- (cid:1) methylation status. We also investigated the structural characteristics of the two ER- (cid:1) promoters, which were both found to be closely associated with a second, downstream, localized and opposite-oriented promoter. However, we could not detect endogenous antisense RNA transcribed from these promoters, which may be involved in epigenetic gene silencing. We also failed to induce ER- (cid:1) promoter methylation by expressing siRNAs in cell lines. Interestingly, by comparing the promoter sequences of ER- (cid:1) with other genes known to be epigenetically inactivated in breast cancers, we iden-tified a sequence motif possibly involved in promoter methylation.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106005608","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic mammotome excisions: papillary lesions","authors":"L. Philpotts","doi":"10.1017/S1470903106004603","DOIUrl":"https://doi.org/10.1017/S1470903106004603","url":null,"abstract":"Papillary lesions of the breast are fairly common on imaging-guided breast biopsy, and the management remains controversial. Due to the heterogeneity of histological findings, papilloma can be a challenge to the pathologist when interpreting core biopsy specimens, so some may desire the entire lesion to be removed to be confident of the diagnosis of a benign papilloma. In appropriate cases, an attempt at removal with vacuum-assisted biopsy appears a reasonable approach with the hopes of establishing a diagnosis, relieving symptoms of nipple discharge, and avoiding the cost and morbidity of surgical intervention. The management of lesions with atypia on mammotome excision will remain controversial and the prudent approach is to recommend complete surgical excision.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106004603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic Science: (May 2006)","authors":"R. Sutherland, J. Scorer","doi":"10.1017/S1470903106005669","DOIUrl":"https://doi.org/10.1017/S1470903106005669","url":null,"abstract":"1. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu MN, Boone E, Haegeman G. Attenuation of mitogenand stress-activated protein kinase1-driven nuclear factor-kappa B gene expression by soy isoflavones does not require estrogenic activity [Abstract]. Cancer Res 2006; 66: 4852–4862. 2. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, Charpin C, Jacquemier J, Birnbaum D. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. [Abstract]. Cancer Res 2006; 66: 4636–4644. 3. Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration [Abstract]. Cancer Res 2006; 66: 4725–4733. 4. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [Abstract]. Cancer Res 2006; 66: 5104–5110. 5. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, Mueller SC. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells [Abstract]. Exp Cell Res 2006; 312: 1240–1253. 6. Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer [Abstract]. Cancer Epidemiol Biomark Prev 2006; 15: 961–966. 7. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer [Abstract]. Mod Pathol 2006; 19: 617–621. 8. Chabottaux V, Sounni NE, Pennington CJ, English WR, van den Brule F, Blacher S, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Edwards DR, Foidart JM, Noel A. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases [Abstract]. Cancer Res 2006; 66: 5165–5172. 9. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival [Abstract]. Cancer Res 2006; 66: 5287–5294. 10. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells [Abstract]. Mol Cell Biol 2006; 26: 3955–3965. 11. Cui XJ, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell migration [Abstract]. Cancer Res 2006; 66: 5304–5313. 12. Deugnier MA, Faraldo MM, Teuliere J, Thiery JP, Medina D, Glukhova MA. Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-D beta cell line [Abstract]. Dev Biol 2006; 293: 414–425. 13. Dolled-Filhart M, McCabe A, Giltnane J, ","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106005669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic Science: (June 2006)","authors":"R. Sutherland, J. Scorer","doi":"10.1017/S1470903106005670","DOIUrl":"https://doi.org/10.1017/S1470903106005670","url":null,"abstract":"1. Adams SA, Matthews CE, Hebert JR, Moore CG, Cunningham JE, Shu XO, Fulton J, Gao YT, Zheng W. Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study [Abstract]. Cancer Epidemiol BiomarPrev 2006; 15: 1170–1178. 2. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Furuta E, Iiizumi M, Mohinta S, Watabe M, Chalfant C, Watabe K. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells [Abstract]. Cancer Res 2006; 66: 5934–5940. 3. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D’Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy [Abstract]. Cancer Res 66: 6421–6431. 4. Cellai C, Laurenzana A, Vannucchi AM, Caporale R, Paglierani M, Di Lollo S, Pancrazzi A, Paoletti F. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086 [Abstract]. Brit J Cancer 2006; 94: 1637–1642. 5. Cui YK, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SAW. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance [Abstract]. Cancer Res 2006; 66: 5950–5959. 6. den Hollander P, Kumar R. Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells [Abstract]. Cancer Res 2006; 66: 5941–5949. 7. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells [Abstract]. Biochem Biophys Res Commun 2006; 345: 271–279. 8. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen [Abstract]. Oncogene 2006; 25: 3994–4008. 9. Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer [Abstract]. Cancer Epidemiol Biomar Prev 2006; 15: 1153–1158. 10. Glinsky GV. Genomic models of metastatic cancer – Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated polycomb group (PcG) protein chromatin silencing pathway [Abstract]. Cell Cycle 2006; 5: 1208–1216. 11. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells [Abstract]. Breast Cancer Res Treat 2006; 97: 263–274. 12. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C,","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106005670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}